We came across a bullish thesis on Genmab A/S (GMAB) on Substack by Oliver | MMMT Wealth. In this article, we will summarize ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $25.00. The ...

Danish biotech (Nasdaq: GMAB) on Saturday revealed that US pharma major (AbbVie (NYSE: ABBV) has filed a complaint in the US ...

Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...

In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other cash-rich undervalued stocks. Currently, big tech and high-growth stocks dominate the stock ...

In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against other best growth stocks to invest in according to analysts. Companies experiencing above-average ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Genmab (GMAB – Research Report) today. The company’s shares closed ...

Assetmark Inc. lowered its position in Genmab A/S (NASDAQ:GMAB – Free Report) by 78.1% during the fourth quarter, Holdings ...

William Blair upped their FY2028 EPS estimates for Genmab A/S in a research note issued on Monday, March 10th. William Blair ...

In trading on Friday, shares of Genmab A/S (Symbol: GMAB) crossed above their 200 day moving average of $24.14, changing hands as high as $24.32 per share. Genmab A/S shares are currently trading ...

We recently compiled a list of the 10 Cash-Rich Undervalued Stocks To Invest In. In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other cash-rich ...